AUGX Insider Trading Activity and SEC Form 4 Filings
AUGX insider trading summary
No open-market insider purchases or sales of Augmedix, Inc. (AUGX) have been reported on SEC Form 4 in the past 12 months.
Latest AUGX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 15, 2024 | Jonathan Hawkins | Chief Revenue Officer | Sell | $2K (1,767 @ $1.19) |
| May 15, 2024 | Paul Ginocchio | Chief Financial Officer | Sell | $3K (2,354 @ $1.19) |
| May 15, 2024 | Saurav Chatterjee | Chief Technology Officer | Sell | $2K (1,767 @ $1.19) |
| May 15, 2024 | Sandra Breber | Chief Operating Officer | Sell | $3K (2,354 @ $1.19) |
| May 15, 2024 | Emmanuel Krakaris | President, CEO, and Secretary | Sell | $4K (3,528 @ $1.19) |
| May 15, 2024 | Ian Shakil | Chief Strategy Officer | Sell | $2K (1,387 @ $1.19) |
| Apr 15, 2024 | Ian Shakil | Chief Strategy Officer | Sell | $2K (500 @ $3.80) |
| Apr 12, 2024 | Ian Shakil | Chief Strategy Officer | Sell | $75K (19,544 @ $3.82) |
| Apr 11, 2024 | Ian Shakil | Chief Strategy Officer | Sell | $97K (24,778 @ $3.93) |
| Apr 10, 2024 | Ian Shakil | Chief Strategy Officer | Sell | $141K (36,467 @ $3.87) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.